97 related articles for article (PubMed ID: 22994085)
1. [Markers of endothelial activation in rheumatoid arthritis].
Shilikina NP; Yunonin IE; Vinogradov AA; Butusova SV
Ter Arkh; 2012; 84(8):29-32. PubMed ID: 22994085
[TBL] [Abstract][Full Text] [Related]
2. [Endothelial dysfunction in rheumatic patients].
Shilkina NP; Butusova SV
Klin Med (Mosk); 2013; 91(4):58-61. PubMed ID: 23879057
[TBL] [Abstract][Full Text] [Related]
3. [Markers of vascular endothelium activation in gout].
Lapkina NA; Baranov AA; Barskova VG; Abaĭtova NE; Iakunina IA
Ter Arkh; 2005; 77(5):62-5. PubMed ID: 15989007
[TBL] [Abstract][Full Text] [Related]
4. [System of microcirculation, markers of vascular wall damage and systematicity of the process in rheumatic diseases].
Shilkina NP; Butusova SV; Driazhenkova IV
Angiol Sosud Khir; 2014; 20(1):27-34. PubMed ID: 24722018
[TBL] [Abstract][Full Text] [Related]
5. Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis.
Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
Scand J Rheumatol; 2009; 38(6):439-44. PubMed ID: 19922018
[TBL] [Abstract][Full Text] [Related]
6. Does reduction of disease activity improve early markers of cardiovascular disease in newly diagnosed rheumatoid arthritis patients?
de Groot L; Jager NA; Westra J; Smit AJ; Kallenberg CG; Posthumus MD; Bijl M
Rheumatology (Oxford); 2015 Jul; 54(7):1257-61. PubMed ID: 25587178
[TBL] [Abstract][Full Text] [Related]
7. Soluble adhesion molecules and anti-endothelial cell antibodies in patients with rheumatoid arthritis complicated by peripheral neuropathy.
Salih AM; Nixon NB; Dawes PT; Mattey DL
J Rheumatol; 1999 Mar; 26(3):551-5. PubMed ID: 10090161
[TBL] [Abstract][Full Text] [Related]
8. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis.
Wållberg-Jonsson S; Cvetkovic JT; Sundqvist KG; Lefvert AK; Rantapää-Dahlqvist S
J Rheumatol; 2002 May; 29(5):875-82. PubMed ID: 12022343
[TBL] [Abstract][Full Text] [Related]
9. Inflammation and microvascular and macrovascular endothelial dysfunction in rheumatoid arthritis: effect of treatment.
Foster W; Carruthers D; Lip GY; Blann AD
J Rheumatol; 2010 Apr; 37(4):711-6. PubMed ID: 20156948
[TBL] [Abstract][Full Text] [Related]
10. Advanced glycation end-products inhibition improves endothelial dysfunction in rheumatoid arthritis.
Syngle A; Vohra K; Garg N; Kaur L; Chand P
Int J Rheum Dis; 2012 Feb; 15(1):45-55. PubMed ID: 22324946
[TBL] [Abstract][Full Text] [Related]
11. [Endothelial damage and circadian blood pressure profile in rheumatoid arthritis].
Shilkina NP; Yunonin IE; Butusova SV; Mikhailova EV; Vinogradov AA
Ter Arkh; 2019 May; 91(5):89-95. PubMed ID: 32598682
[TBL] [Abstract][Full Text] [Related]
12. Circulating endothelial cells and rheumatoid arthritis: relationship with plasma markers of endothelial damage/dysfunction.
Foster W; Shantsila E; Carruthers D; Lip GY; Blann AD
Rheumatology (Oxford); 2009 Mar; 48(3):285-8. PubMed ID: 19153145
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis.
Dessein PH; Joffe BI; Singh S
Arthritis Res Ther; 2005; 7(3):R634-43. PubMed ID: 15899050
[TBL] [Abstract][Full Text] [Related]
14. Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis.
Klimiuk PA; Fiedorczyk M; Sierakowski S; Chwiecko J
Scand J Rheumatol; 2007; 36(5):345-50. PubMed ID: 17963163
[TBL] [Abstract][Full Text] [Related]
15. Altered levels of soluble adhesion molecules in patients with rheumatoid arthritis complicated by peripheral neuropathy.
El M; Ashour S; Moustafa H; Ahmed I
J Rheumatol; 2002 Jan; 29(1):57-61. PubMed ID: 11824972
[TBL] [Abstract][Full Text] [Related]
16. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis.
Steiner G; Studnicka-Benke A; Witzmann G; Höfler E; Smolen J
J Rheumatol; 1995 Mar; 22(3):406-12. PubMed ID: 7783054
[TBL] [Abstract][Full Text] [Related]
17. Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease.
de Groot L; Hinkema H; Westra J; Smit AJ; Kallenberg CG; Bijl M; Posthumus MD
Arthritis Res Ther; 2011; 13(6):R205. PubMed ID: 22168993
[TBL] [Abstract][Full Text] [Related]
18. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity.
Kerekes G; Szekanecz Z; Dér H; Sándor Z; Lakos G; Muszbek L; Csipö I; Sipka S; Seres I; Paragh G; Kappelmayer J; Szomják E; Veres K; Szegedi G; Shoenfeld Y; Soltész P
J Rheumatol; 2008 Mar; 35(3):398-406. PubMed ID: 18203326
[TBL] [Abstract][Full Text] [Related]
19. Increased serum interleukin 22 in patients with rheumatoid arthritis and correlation with disease activity.
da Rocha LF; Duarte ÂL; Dantas AT; Mariz HA; Pitta Ida R; Galdino SL; Pitta MG
J Rheumatol; 2012 Jul; 39(7):1320-5. PubMed ID: 22589261
[TBL] [Abstract][Full Text] [Related]
20. [Cerebral perfusion, arterial hypertension and endothelial dysfunction in rheumatoid arthritis].
Shilkina NP; Spirin NN; Yunonin IE; Vinogradov AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(3. Vyp. 2):68-75. PubMed ID: 31184627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
